Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

August 06, 2026 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam, Subject : Outcome of Board Meeting-August 06, 2026 Stock Code : BSE – 539787, NSE – HCG Reference : Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) Further to our intimation dated July 27, 2026, and pursuant to Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company at its meeting held on August 06, 2026, has, inter alia, considered and approved the following agenda: i. Unaudited Financial Results of the Company (Standalone and Consolidated), for the quarter ended June 30, 2026. ii. Re-appointment of M/s. Rao Murthy & Associates (Firm Registration No. 000065), Cost Accountants, Bengaluru as the Cost Auditor of the Company for the financial year 2026-27. iii. Further investment of up to INR 16 Crore in HCG Rajkot Hospitals LLP, wholly owned subsidiary of the Company. In this regard, please find enclosed herewith the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The financial results are also being made available on the website of the Company and can be accessed at: https://www.hcgoncology.com/ The meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 06.50 p.m. Kindly take the intimation on record and acknowledge receipt of the same. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a. HealthCare Global Enterprises Limited Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027 Corp Off: #3, G-Floor, Tower Block, Unity Buildings Complex, Mission Road, Bengaluru - 560 027, Karnataka, India 91 80 4660 7700 | Emall-query@hcgel.com | Website - www.hcgoncology.com | CIN: L15200KA1998PLC023489 Ahmedabad | Bengaluru | Bhavnagar | Chennai | Cuttack | Hubballi | Indore | Jaipur | Kalaburagi | Kenya | Kolkata | Mumbai | Nagpur | Nashik | Ongole | Rajkot | Ranchi | Shimoga | Vadodara | Vijayawada | Vizag HealthCare Global Enterprises Limited CIN: Ll5200KAl998PLC023489 Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 (Rs. in Lakhs except share data) SI. Quarter Preceding quarter Corresponding Previous year No. Particulars ended ended quarter ended ended 30 June 2026 31 March 2026 30 June 2025 31 March 2026 Unaudited (Refer note 2) Unaudited Audited I Income (a) Revenue from operations 37,525 34,847 32,593 135,937 (b) Income from government grant 141 174 116 593 (c) Other income 956 1,492 794 2,967 Total income 38,622 36,513 33,503 139,497 2 Expenses (a) Purchases of medical and non-medical items 9,561 9,513 8,424 35,864 (b) Changes in inventories (360) (308) (361) (548) (c) Employee benefits expense 5,967 5,078 5,641 21,192 (d) Finance costs 2,173 2,019 2,430 8,646 (e) Depreciation and amortisation expen e 3,957 3,130 2,825 11,980 ( f) Medical consultancy charges 7,734 6,675 6,428 26,343 (g) Other expenses 8,842 6,549 7,592 29,520 Total expenses 37,874 32,656 32,979 132,997 3 Profit before exceptional items and tax (1-2) 748 3,857 524 6,500 4 Exceptional items (refer note 3) (4,752) (5,538) 5 Profit /(loss) before tax (3+4) 748 (895) 524 962 6 Tax expense urrent tax (refer note 7) 362 (820) "34 404 -Deferred tax (172) (228) ( 155) (900) Total tax expense 190 (1,048) 179 (496) 7 Profit for the period /year (5-6) 558 153 345 1,458 8 Other comprehensive income/ (loss) Items that will not be reclassified subsequently to profit or loss -Remeasurements of the defined benefit plans (14) II -Income tax effect on above 3 (3) Other comprehensive income/ (loss) for the period / - ( 11) - 8 year, net of tax 9 Total comprehensive income for the period/ year (7+8) 558 142 345 1,466 10 Paid-up equity share capital (Face value of Rs. 10 each) 14,930 14,930 13,942 14,930 II Reserves, i.e., 'Other equity' 145,548 12 Earnings/(loss) per equity share (face value of Rs. 10 Not annualised Not annualised Not annualised Annualised each) (a) Basic (Rs.) (refer note 4) 0.37 0.11 0.25 103 (b) Diluted (Rs) (refer note 4) 0.37 0.11 0.24 103 See accompanying notes to the Standalone Financial Results HealthCare Global Enterprises Limited CIN: L15200KA1998PLC023489 Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India STATEMENT OF UNAUDITED STANDALONE Fl ANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 Notes: I This statement of standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter ended 30 June 2026 has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 06 August 2026. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in tern1s of Regulation 33 of the SEBI ( Listing Obligation and Disclosure requirements) Regulations, 2015. The Statement has been subjected to limited review by the statuto1y auditor of the Company. The report of the statuto1y auditor is unqualified. 2 The figures for preceeding quarter ended 31 March 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the end of the third quaiter of the previous financial year, which were subject to limited review by the statutory auditors of the Company. Exceptional items: (i) During the quarter and previous year ended 31 March 2026, the management committed to a plan to divest the Company's entire equity interest in BACC Healthcare Private Limited ("BACC"), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Pursuant to the investor outTeach process, non-binding offers were received from potential investors. Accordingly, the Company's investment in BACC, which was previously carried at cost less provision for diminution in value of investment, was reclassified as an "Investments classified as held for sale". Consequently, the investment was measured at the lower of its carrying amount and fair value less costs to sell. Accordingly, an impairment loss of Rs. 3,752 lakhs was recognised as an exceptional item for the preceding quarter and previous year ended 31 March 2026 based on the fair value of the consideration receivable, net of related expenses. During the current quarter, based on the recommendation of the Audit Committee, and pursuant to the approval of the Board of Directors at its meeting held on 19 May 2026, the Company has completed the divestment of its entire equity intere t in BA C to lnviga Healthcare Fund I and it nominee, a related party. for a consideration ol'Rs. 3,764 lakh on 29 June 2026. Of the said consideration, Rs. 2,823 lakhs has been received upfront and the balance Rs. 941 lakhs is receivable within 18 months from the date of sale. onsequent to completion of the transaction, BA has ceased to be a subsidiary of the Company with effect from 30 June 2026. (ii) During the quarter and previous year ended 31 March 2026, the recoverable amount of the Company' inves [Showing first 8,000 characters — download PDF for full document]